Novo Nordisk's Wegovy has received accelerated approval for use in patients with metabolic dysfunction-associated ...

Novo Nordisk's GLP-1 drugs have been under considerable competitive pressure in the last few months, so the company will be ...

Proponents of a greatest-hits menu will say it's diversity on a plate, but I don't buy it. To me, the popular and familiar ...

The company said Friday that it received FDA approval for a new Wegovy indication as a treatment of a fatty liver disease known as metabolic dysfunction-associated steatohepatitis, or MASH, in adults ...

The stock is rebounding after a rough July that saw $70 billion wiped off its market value and a leadership change, with new ...